[Skip to Content]
[Skip to Content Landing]
Views 5,321
Citations 0
News From the Food and Drug Administration
October 17, 2017

Antibacterial Inhibits Resistance

JAMA. 2017;318(15):1432. doi:10.1001/jama.2017.15282

A new antibacterial drug that inhibits certain resistance mechanisms has received FDA approval for treating adults with complicated urinary tract infections (cUTIs), including pyelonephritis.

Marketed as Vabomere, the drug is aimed at cUTIs caused by specific susceptible Enterobacteriaceae—Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex. The medication combines the antibacterial meropenem with vaborbactam, a β-lactamase inhibitor that helps prevent certain serine β-lactamases such as K pneumoniae carbapenemase from degrading meropenem. Vaborbactam has no antibacterial activity.

First Page Preview View Large
First page PDF preview
First page PDF preview